“Optimizing the Treatment Sequence: The Cumulative Clinical Benefit of Treatment Initiation With Deucravacitinib Versus Apremilast over 52 Weeks in Patients With Moderate to Severe Plaque Psoriasis from the POETYK PSO-1 Trial”. SKIN The Journal of Cutaneous Medicine 6, no. 6 (November 16, 2022): s62. Accessed October 6, 2025. https://skin.dermsquared.com/skin/article/view/1817.